AAA
KYMR icon

Affinity Asset Advisors’s Kymera Therapeutics KYMR Stock Holding History

Affinity Asset Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100,000
Closed -$2.74M – 103
2025
Q1 		$2.74M Buy
100,000
+60,000
+150% +$2.19M 0.26% 59
2024
Q4 		$1.61M Buy
+40,000
New +$1.81M 0.22% 62

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Affinity Asset Advisors's KYMR Position: Q2 2025 in Review

Affinity Asset Advisors sold out of Kymera Therapeutics (KYMR) in Q2 2025, closing a stake of 100,000 shares — an estimated $2.74M sold.

Affinity Asset Advisors first reported a position in KYMR in Q4 2024 and held it in 2 quarters. The position peaked at $2.74M in Q1 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q2 2025.

  • Affinity Asset Advisors reported no remaining Kymera Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 100,000 Kymera Therapeutics shares in Q2 2025, an estimated $2.74M.
  • Affinity Asset Advisors first reported a position in Kymera Therapeutics in Q4 2024 and held it in 2 quarters.
  • Affinity Asset Advisors's Kymera Therapeutics position peaked at $2.74M in Q1 2025.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2025.

Based on Affinity Asset Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.